secwatch.observer — SEC 8-K summary
======================================

Issuer:     RenovoRx, Inc. (RNXT)
CIK:        0001574094
Form:       8-K
Filed at:   2023-08-17T23:59:59+00:00
Accession:  0001493152-23-029240
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

RenovoRx Q2 net loss $2.3M; positive Phase III data shows 8-month progression delay
--------------------------------------------------------------------------------

- Net loss $2.3M vs $2.6M year ago; cash $6.0M; R&D $1.9M, G&A $1.4M.
- Phase III TIGeR-PaC: 8-month progression delay, 6-month OS benefit, 65% fewer adverse events.
- Collaboration with Imugene to deliver oncolytic immunotherapy via TAMP platform for metastatic disease.
- Appointed Robert Spiegel to Board, Margaret Tempero to SAB, Leesa Gentry as SVP Clinical Ops.
- Closed $5M registered direct offering and concurrent private placement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1574094/000149315223029240/0001493152-23-029240-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1574094/000149315223029240/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-029240

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer